Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for chinese non-small cell lung cancer patients

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Wu, Wenting ^a,b   Li, Huan ^a   Wang, Huibo ^d   Zhao, Xueying ^a   Gao, Zhiqiang ^c   Qiao, Rong ^c   Zhang, Wei ^c   Qian, Ji ^a   Wang, Jiucun ^a   Chen, Hongyan ^a   Wei, Qingyi ^e   Han, Baohui ^c   Lu, Daru ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d Heerskink School of Medicine   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GLUTAMINE; LYSINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; ERCC2 PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LOG RANK TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; ONCOGENE; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM; XPD GENE; ASIAN; CHINA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ETHNOLOGY; GENE FREQUENCY; GENETICS; LUNG TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84859047794     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033200     Document Type: Article

References (35)

1. Parkin DM, Pisani P, Ferlay J, (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-41.
2. Einhorn LH, (2008) First-line chemotherapy for non-small-cell lung cancer: Is there a superior regimen based on histology? J Clin Oncol 26: 3485-6.
3. Jemal A, Thomas A, Murray T, Thun M, (2002) Cancer statistics, 2002. Ca-Cancer J Clin 52: 23-47.
4. Brundage MD, Davies D, Mackillop WJ, (2002) Prognostic factors in non-small cell lung cancer- A decade of progress. Chest 122: 1037-57.
5. Evans WE, McLeod HL, (2003) Drug therapy- Pharmacogenomics- Drug disposition, drug targets, and side effects. New Engl J Med 348: 538-49.
6. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-79.
7. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, et al. (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98: 1336-43.
8. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, et al. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-601.
9. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-91.
10. Wu Q, Christensen LA, Legerski RJ, Vasquez KM, (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. Embo Reports 6: 551-6.
11. Spitz MR, Wu XF, Wang YF, Wang LE, Shete S, et al. (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61: 1354-7.
12. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, et al. (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21: 551-5.
13. Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, et al. (2007) Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genom 17: 897-905.
14. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA, (1999) Polymorphisms in the DNA repair gene XPD: Correlations with risk and age at onset of basal cell carcinoma. Cancer Epidem Biomar 8: 77-81.
15. Gao WM, Romkes M, Day RD, Siegfried JM, Luketich JD, et al. (2003) Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis 24: 1671-6.
16. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, et al. (2009) Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics. J Clin Oncol 27: 3540-6.
17. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, et al. (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8.
18. Wu WT, Zhang W, Qiao R, Chen D, Wang HB, et al. (2009) Association of XPD Polymorphisms with Severe Toxicity in Non-Small Cell Lung Cancer Patients in a Chinese Population. Clin Cancer Res 15: 3889-95.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and Response Criteria of the Eastern-Cooperative-Oncology-Group. Am J Clin Oncol-Canc 5: 649-55.
20. Wakefield J, (2007) A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet 81: 208-27.
21. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, et al. (2001) Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 22: 593-7.
22. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, et al. (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Annals of Oncology 17: 668-75.
23. Isla D, Sarries C, Rosell R, Alonso G, Domine M, et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology 15: 1194-203.
24. Laine JP, Mocquet V, Bonfanti M, Braun C, Egly JM, et al. (2007) Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription. DNA Repair 6: 1264-70.
25. Monaco R, Rosal R, Dolan MA, Pincus MR, Freyer G, et al. (2009) Conformational effects of a common codon 751 polymorphism on the C-terminal domain of the xeroderma pigmentosum D protein. J Carcinog 8: 12.
26. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, et al. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-6.
27. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, et al. (2009) Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 10: 859-64.
28. Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, et al. (2001) Functional significance of XPD polymorphic variants: Attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 61: 7430-4.
29. Heist RS, Zhou W, Wang ZX, Liu G, Neuberg D, et al. (2008) Circulating 25-Hydroxyvitamin D, VDR Polymorphisms, and Survival in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 26: 5596-602.
30. Yin M, Yan JR, Voutsina A, Tibaldi C, Christiani DC, et al. (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis. Lung Cancer 72: 370-7.
31. Liang G, Xing D, Miao X, Tan W, Yu C, et al. (2003) Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 105: 669-73.
32. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q, (2002) DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 128: 1084-8.
33. Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, et al. (2000) A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 60: 5612-6.
34. Ring BZ, Seitz RS, Beck RA, Shasteen WJ, Soltermann A, et al. (2009) A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Modern Pathol 22: 1032-43.
35. Chng W, Santana-Davila R, Van Wier S, Ahmann GJ, Jalal SM, et al. (2006) Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 20: 807-13.